Francesca Chiarini

List of Publications by Citations

42 papers	2,280 citations	25 h-index	43 g-index
43 ext. papers	2,513 ext. citations	5.9 avg, IF	4.51 L-index

#	Paper	IF	Citations
42	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*, **2012**, 3, 1068-111	3.3	250
41	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*, **2012**, 3, 954-87	3.3	214
40	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. *Oncotarget*, **2010**, 1, 89-103	3.3	200
39	Current treatment strategies for inhibiting mTOR in cancer. *Trends in Pharmacological Sciences*, **2015**, 36, 124-35	13.2	195
38	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. *Cancer Research*, **2010**, 70, 8097-107	10.1	136
37	Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. *Cancer Research*, **2009**, 69, 3520-8	10.1	106
36	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. *Oncotarget*, **2012**, 3, 371-94	3.3	98
35	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2010**, 1803, 991-1002	4.9	97
34	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 449-463	4.9	81
33	The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. *Cancer Research*, **2007**, 67, 4287-94	10.1	75
32	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2015**, 1853, 14-26	4.9	58
31	Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. *FASEB Journal*, **2009**, 23, 957-66	0.9	58
30	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). *British Journal of Haematology*, **2012**, 156, 205-12	4.5	55
29	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. *Oncotarget*, **2012**, 3, 811-23	3.3	53
28	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2011**, 226, 822-31	7	52
27	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. *Oncotarget*, **2012**, 3, 1615-28	3.3	51
26	Advances in targeting signal transduction pathways. *Oncotarget*, **2012**, 3, 1505-21	3.3	39

25	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 729-42	6.4	34
24	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. *Journal of Hematology and Oncology*, **2016**, 9, 114	22.4	33
23	Activity of the selective IB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. *Cell Cycle*, **2012**, 11, 2467-75	4.7	32
22	Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. *Advances in Biological Regulation*, **2014**, 56, 6-21	6.2	31
21	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. *Oncotarget*, **2014**, 5, 7886-901	3.3	30
20	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-B. *Oncotarget*, **2016**, 7, 1323-40	3.3	30
19	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. *Oncotarget*, **2015**, 6, 10399-414	3.3	29
18	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. *Cell Cycle*, **2014**, 13, 2237-47	4.7	28
17	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	24
16	K562 cell proliferation is modulated by PLC1 through a PKC-mediated pathway. *Cell Cycle*, **2013**, 12, 1713-21	4.7	23
15	Targeting Wnt/-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2020**, 235, 5413-5428	7	23
14	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). *International Journal of Oncology*, **2014**, 45, 909-18	4.4	19
13	The Role Played by Wnt/-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	18
12	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. *Advances in Biological Regulation*, **2012**, 52, 214-27	6.2	18
11	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	17
10	Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. *Advances in Biological Regulation*, **2018**, 68, 2-9	6.2	14
9	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. *Advances in Biological Regulation*, **2013**, 53, 146-55	6.2	14
8	Phospholipase C-1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. *Advances in Biological Regulation*, **2019**, 71, 1-9	6.2	12

7	Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model. *Cells*, **2019**, 8,	7.9	9
6	PLC1a and PLC1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. *Journal of Cellular Physiology*, **2015**, 230, 587-94	7	7
5	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. *Cells*, **2020**, 9,	7.9	7
4	Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm. *Mechanisms of Ageing and Development*, **2021**, 197, 111515	5.6	3
3	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. *Advances in Biological Regulation*, **2019**, 74, 100649	6.2	1
2	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways **2013**, 331-372		1
1	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma.. *Cell Death and Disease*, **2022**, 13, 346	9.8	1